SUPERNUS PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Cash and Cash Equivalents, Period Increase (Decrease) of $33.91 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-01
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $18.38M, a 51.99% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $20.19M, a 11.23% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $2.14M, a 86.90% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$6.80M.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $33.91M, a 3.06% increase from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $32.90M.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$2.90M, a 184.84% decline from fiscal 2014.
- SUPERNUS PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $3.42M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $18.38M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $38.57M derived: sum of 2 quarters · filed 2018-03-01 | $40.70M derived: sum of 3 quarters · filed 2018-03-01 | $33.91M 10-K · filed 2018-03-01 | ||||
| 2017-09-30 | $20.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $22.32M derived: sum of 2 quarters · filed 2017-11-09 | $15.53M 10-Q · filed 2017-11-09 | $27.62M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2017-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$4.66M 10-Q · filed 2017-08-03 | $7.43M derived: sum of 3 quarters · filed 2018-03-01 | $25.58M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2017-03-31 | -$6.80M 10-Q · filed 2017-05-09 | $5.29M derived: sum of 2 quarters · filed 2018-03-01 | $23.44M derived: sum of 3 quarters · filed 2018-03-01 | $39.77M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-12-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $30.24M derived: sum of 2 quarters · filed 2018-03-01 | $46.57M derived: sum of 3 quarters · filed 2018-03-01 | $32.90M 10-K · filed 2018-03-01 | ||||
| 2016-09-30 | $18.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $34.48M derived: sum of 2 quarters · filed 2017-11-09 | $20.81M 10-Q · filed 2017-11-09 | $28.66M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $16.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.66M 10-Q · filed 2017-08-03 | $2.00M 10-Q · filed 2016-08-05 | $10.52M derived: sum of 3 quarters · filed 2018-03-01 | $3.70M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | -$13.67M 10-Q · filed 2017-05-09 | -$14.32M 10-Q · filed 2016-05-10 | -$5.81M derived: sum of 2 quarters · filed 2018-03-01 | -$12.63M derived: sum of 3 quarters · filed 2018-03-01 | -$5.33M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $7.86M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $1.04M derived: sum of 2 quarters · filed 2018-03-01 | $8.34M derived: sum of 3 quarters · filed 2018-03-01 | -$2.90M 10-K · filed 2018-03-01 | -$2.24M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | -$6.82M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $483.00K derived: sum of 2 quarters · filed 2017-01-23 | -$10.76M 10-Q/A · filed 2017-01-20 | -$10.10M 10-Q · filed 2015-11-09 | -$12.14M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $7.30M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | -$3.94M 10-Q/A · filed 2017-01-23 | -$3.29M 10-Q · filed 2015-08-07 | -$5.32M derived: sum of 3 quarters · filed 2017-03-16 | $20.50M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$11.24M 10-Q/A · filed 2017-01-20 | -$10.59M 10-Q · filed 2015-05-06 | -$12.62M derived: sum of 2 quarters · filed 2017-03-16 | $13.20M derived: sum of 3 quarters · filed 2017-03-16 | $12.91M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$1.38M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $24.44M derived: sum of 2 quarters · filed 2017-03-16 | $24.14M derived: sum of 3 quarters · filed 2017-03-16 | $3.42M 10-K · filed 2017-03-16 | ||||
| 2014-09-30 | $25.82M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $25.53M derived: sum of 2 quarters · filed 2017-01-20 | $4.80M 10-Q/A · filed 2017-01-20 | $14.84M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-06-30 | -$296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$21.02M 10-Q · filed 2015-08-07 | -$10.99M derived: sum of 3 quarters · filed 2017-01-20 | -$21.95M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2014-03-31 | -$20.73M 10-Q · filed 2015-05-06 | -$10.69M derived: sum of 2 quarters · filed 2017-01-20 | -$21.66M derived: sum of 3 quarters · filed 2017-01-20 | -$6.66M derived: sum of 4 quarters · filed 2017-01-20 | ||||
| 2013-12-31 | $10.04M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | -$927.00K derived: sum of 2 quarters · filed 2017-01-20 | $14.07M derived: sum of 3 quarters · filed 2017-01-20 | -$7.32M 10-K/A · filed 2017-01-20 | ||||
| 2013-09-30 | -$10.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $4.04M derived: sum of 2 quarters · filed 2014-11-12 | -$17.36M 10-Q · filed 2014-11-12 | -$467.00K derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$6.39M 10-Q · filed 2014-08-12 | $10.49M derived: sum of 3 quarters · filed 2015-03-12 | -$13.34M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$21.39M 10-Q · filed 2014-05-13 | -$4.50M derived: sum of 2 quarters · filed 2015-03-12 | -$28.33M derived: sum of 3 quarters · filed 2015-03-12 | $3.04M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $16.89M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$6.94M derived: sum of 2 quarters · filed 2015-03-12 | $24.44M derived: sum of 3 quarters · filed 2015-03-12 | -$8.24M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | -$23.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $7.55M derived: sum of 2 quarters · filed 2013-11-13 | -$25.13M 10-Q · filed 2013-11-13 | $6.93M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-06-30 | $31.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$1.30M 10-Q · filed 2013-08-14 | $30.76M derived: sum of 3 quarters · filed 2014-03-21 | $30.68M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2012-03-31 | -$32.68M 10-Q · filed 2013-05-15 | -$618.00K derived: sum of 2 quarters · filed 2014-03-21 | -$695.00K derived: sum of 3 quarters · filed 2014-03-21 | -$4.98M derived: sum of 4 quarters · filed 2014-03-21 | ||||
| 2011-12-31 | $32.06M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $31.98M derived: sum of 2 quarters · filed 2014-03-21 | $27.70M derived: sum of 3 quarters · filed 2014-03-21 | $24.80M 10-K · filed 2014-03-21 | ||||
| 2011-09-30 | -$77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$4.36M derived: sum of 2 quarters · filed 2012-11-02 | -$7.26M 10-Q · filed 2012-11-02 | |||||
| 2011-06-30 | -$4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$7.18M 10-Q · filed 2012-08-13 | ||||||
| 2011-03-31 | -$2.90M 10-Q · filed 2012-06-08 | |||||||
| 2010-12-31 | -$7.67M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |